We are live on
!
Find out more
PCA
Private Capital Advisors Portfolio holdings
AUM
$1.15B
1-Year Est. Return
43.46%
This Fund
S&P 500
This Quarter
Est. Return
+5.13%
1 Year Est. Return
+43.46%
3 Year Est. Return
+131.91%
5 Year Est. Return
+229.29%
10 Year Est. Return
+757.55%
AUM
$319M
AUM Growth
+$18.9M
(+6.3%)
Cap. Flow
+$6.94M
Cap. Flow
% of AUM
2.17%
Top 10 Holdings %
Top 10 Hldgs %
37.77%
Holding
106
New
6
Increased
17
Reduced
26
Closed
10
Avg Time Held
12.4
quarters
Top 10 Avg Time Held
5.1
quarters
Top 20 Avg Time Held
7.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Karyopharm Therapeutics
KPTI
|
+$6.87M |
| 2 |
IBM
IBM
|
+$6.33M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$3.96M |
| 4 |
Stryker
SYK
|
+$2.76M |
| 5 |
Cigna
CI
|
+$2.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$3.67M |
| 2 |
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
|
+$1.74M |
| 3 |
iShares Biotechnology ETF
IBB
|
+$1.38M |
| 4 |
KKR & Co
KKR
|
+$1.27M |
| 5 |
Targa Resources
TRGP
|
+$841K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.66% |
| 2 | Technology | 16.82% |
| 3 | Communication Services | 16.5% |
| 4 | Industrials | 8.67% |
| 5 | Miscellaneous | 6.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Eli Lilly
LLY
$1.04T
| $32.9M | 10.31% |
385,549
| – | – |
2016 Q2
8 quarters
|
|
2
Apple
AAPL
$4.98T
| $14M | 4.37% |
301,572
+3,320
| +1% | +$151K |
2013 Q2
20 quarters
|
|
3
Alphabet (Google) Class A
GOOGL
$4.33T
| $12.9M | 4.03% |
227,760
+6,100
| +3% | +$332K |
2015 Q3
11 quarters
|
|
|
4
Meta Platforms (Facebook)
META
$1.94T
| $9.99M | 3.13% |
51,418
-20,285
| -28% | -$3.67M |
2015 Q2
12 quarters
|
|
5
Blackstone
BX
$82.6B
| $9.29M | 2.91% |
288,660
+2,573
| +0.9% | +$81.9K |
2013 Q2
20 quarters
|
|
|
6
iShares Biotechnology ETF
IBB
$10.2B
| $8.76M | 2.74% |
79,757
-12,860
| -14% | -$1.38M |
2017 Q2
4 quarters
|
|
7
Visa
V
$744B
| $8.63M | 2.7% |
65,133
+1,858
| +3% | +$239K |
2016 Q4
6 quarters
|
|
8
UnitedHealth
UNH
$339B
| $8.25M | 2.59% |
33,632
-75
| -0.2% | -$18K |
2014 Q3
15 quarters
|
|
9
Thermo Fisher Scientific
TMO
$245B
| $8.02M | 2.51% |
38,738
+454
| +1% | +$96.4K |
2015 Q2
12 quarters
|
|
|
10
Cigna
CI
$74.7B
| $7.89M | 2.47% |
46,442
+13,432
| +41% | +$2.33M |
2018 Q1
1 quarter
|
|
11
DELISTED
Paramount Global Class B
PARA
| $7.81M | 2.45% |
138,950
-2,580
| -2% | -$135K |
2013 Q2
20 quarters
|
|
12
Intel
INTC
$543B
| $7.75M | 2.43% |
155,916
-325
| -0.2% | -$17.3K |
2016 Q2
8 quarters
|
|
|
RTN
13
DELISTED
Raytheon Company
RTN
| $7.62M | 2.39% |
39,433
-70
| -0.2% | -$14.7K |
2016 Q1
9 quarters
|
|
14
Adobe
ADBE
$92B
| $7.54M | 2.36% |
30,914
-125
| -0.4% | -$29.6K |
2016 Q1
9 quarters
|
|
|
15
Karyopharm Therapeutics
KPTI
$9.69M
| $7.08M | 2.22% |
+27,793
| New | +$6.87M |
2018 Q2
0 quarters
|
|
16
Enterprise Products Partners
EPD
$77.8B
| $7M | 2.19% |
252,947
+2,625
| +1% | +$71.8K |
2013 Q2
20 quarters
|
|
|
17
Stryker
SYK
$108B
| $7M | 2.19% |
41,435
+16,440
| +66% | +$2.76M |
2016 Q1
9 quarters
|
|
18
Amgen
AMGN
$223B
| $6.89M | 2.16% |
37,309
+934
| +3% | +$165K |
2018 Q1
1 quarter
|
|
19
Cisco
CSCO
$454B
| $6.74M | 2.11% |
156,700
-350
| -0.2% | -$15.3K |
2017 Q3
3 quarters
|
|
20
Comcast
CMCSA
$74.1B
| $6.43M | 2.01% |
195,943
-101
| -0.1% | -$3.29K |
2013 Q2
20 quarters
|
|
|
21
IBM
IBM
$217B
| $6.35M | 1.99% |
47,541
+45,397
| +2,117% | +$6.33M |
2013 Q2
20 quarters
|
|
22
Pfizer
PFE
$162B
| $6.24M | 1.96% |
181,336
+22,956
| +14% | +$784K |
2013 Q2
20 quarters
|
|
23
Union Pacific
UNP
$168B
| $6.22M | 1.95% |
43,920
| – | – |
2013 Q2
20 quarters
|
|
24
MPLX
MPLX
$57.7B
| $5.48M | 1.72% |
160,641
+1,886
| +1% | +$65.6K |
2016 Q4
6 quarters
|
|
25
LyondellBasell Industries
LYB
$19.4B
| $5.35M | 1.68% |
48,675
-120
| -0.2% | -$13.2K |
2017 Q3
3 quarters
|
|
Similar funds
WB
AIC
CFP
HT
AA
CIG
CIS
FWM
Private Capital Advisors's Q2 2018 Portfolio in Review
As of Q2 2018, Private Capital Advisors held 106 positions worth $319M, up 6.3% from $300M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Private Capital Advisors's Q2 2018 filing shows 6 new, 17 increased, 26 reduced and 10 closed positions. Its largest new stake was Karyopharm Therapeutics: 27,793 shares worth $7.08M. The largest sale was Meta Platforms (Facebook), an estimated $3.67M.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 27% a quarter earlier, followed by Technology and Communication Services.
- Private Capital Advisors's largest Q2 2018 buy was Karyopharm Therapeutics: 27,793 shares worth $7.08M.
- Private Capital Advisors added most to IBM in Q2 2018, an estimated $6.33M increase.
- Private Capital Advisors's biggest Q2 2018 reduction was Meta Platforms (Facebook), cutting an estimated $3.67M.
- Private Capital Advisors fully exited ARMO BioSciences, Inc. Common Stock in Q2 2018, selling an estimated $1.74M.
- Private Capital Advisors's ten largest holdings make up 38% of its $319M portfolio in Q2 2018.
- Private Capital Advisors opened 6 new positions and closed 10 in Q2 2018.
- Private Capital Advisors's portfolio value rose 6.3% quarter-over-quarter to $319M.
Based on Private Capital Advisors's 13F filing for Q2 2018, filed 10 Jul 2018.